Related Experiment Videos
Lemierre's syndrome: One rare disease-Two case studies
Christine Le1, Dean Gennaro2, Derek Marshall1
1Touro College of Pharmacy, New York, New York.
Journal of Clinical Pharmacy and Therapeutics
|November 29, 2018
Summary
Lemierre's syndrome, a serious infection often mistaken for a cold, can be effectively treated with shorter courses of metronidazole. This study suggests exploring briefer metronidazole durations for Fusobacterium necrophorum infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Internal Medicine
Background:
- Lemierre's syndrome is frequently misdiagnosed due to non-specific initial symptoms.
- Fusobacterium necrophorum is the primary pathogen implicated in Lemierre's syndrome.
- Current treatment guidelines recommend a prolonged 6-week course of beta-lactam antibiotics and metronidazole.
Observation:
- Two cases of Lemierre's syndrome involving internal jugular vein thrombophlebitis and F. necrophorum bacteremia are presented.
- Case 1 received 6 weeks of beta-lactam and 4 weeks of metronidazole.
- Case 2 received 4 weeks of beta-lactam and 2 weeks of metronidazole.
Findings:
- Both cases demonstrated successful treatment outcomes.
- Shorter durations of metronidazole (2-4 weeks) were effective in these patients.
- This challenges the necessity of the standard 6-week metronidazole regimen.
Implications:
- Shorter metronidazole courses may be sufficient for treating Lemierre's syndrome.
- Further clinical trials are warranted to validate reduced metronidazole therapy durations.
- Optimizing treatment length could reduce antibiotic exposure and potential side effects.